This event has already taken place!

AMR research in a post pandemic world

September 18, 2020
Time zone: Stockholm, GMT+01:00

Managing COVID-19 and AMR

How do we simultaneously manage the acute COVID-19 pandemic and escalating antibiotic resistance?

The speakers in this session will discuss how we can build upon knowledge and behaviours from the COVID-19 pandemic to create and sustain awareness and action to address AMR.

Questions that will be discussed include:

  • The COVID-19 pandemic has created awareness of infection biology and community understanding infection prevention and control. How can we build on this knowledge to support understanding of AMR?
  • Funding and policy efforts are highly focused on COVID-19. What does the clinical and scientific communities need to do to continue to raise awareness of the AMR topic?

Moderator: Constance Schultsz (University of Amsterdam)

Constance Schultsz is a medical microbiologist at the Amsterdam UMC, University of Amsterdam, which she joined in 2008. Since 2016, she has been a Professor of Global Health and Deputy Head of the Department of Global Health, and Executive Board Member of the Amsterdam Institute for Global Health and Development (AIGHD). From 2003 to 2008, she headed the Microbiology Department at the Oxford University Clinical Research Unit in Ho Chi Minh City, Vietnam. Her research interests include antimicrobial drug resistance and emerging infectious diseases, which she studies in an international context using interdisciplinary approaches, ranging from molecular biology studies to implementation research. She carries out her research in collaboration with epidemiologists, clinicians, biologists, social scientists such as anthropologists and economists, and computational scientists.


Charu Kaushic (GloPID-R)

Charu Kaushic is the Scientific Director of the Canadian Institutes of Health Research (CIHR)-Institute of Infection and Immunity and a tenured Full Professor in the Department of Pathology and Molecular Medicine in McMaster University, Hamilton, Canada.  In her role as the Scientific Director for CIHR-III, Dr. Kaushic is responsible for making decisions for CIHR strategic investments in the area of infection and immunity, nationally and internationally. She also represents CIHR and Government of Canada at various national and international forums related to infectious diseases. In this capacity she serves as a Co-Chair of GloPID-R, a global consortium of funders in pandemic preparedness and emergency response research. She also represents Canada on the JPIAMR Steering Committee. During the COVID-19 pandemic, she has been closely involved in shaping CIHR’s research response to the pandemic and is serving on COVID-19 National Immunity Task Force. Dr. Kaushic is an immunologist by training and has an active interdisciplinary research program in women’s reproductive health, examining susceptibility and immune responses to sexually transmitted viruses, HIV-1 and HSV-2.

Steven Hoffman (Global Strategy Lab)

Dr. Steven J. Hoffman is the Dahdaleh Distinguished Chair in Global Governance & Legal Epidemiology and a Professor of Global Health, Law, and Political Science at York University, the Director of the Global Strategy Lab, and the Director of the WHO Collaborating Centre on Global Governance of Antimicrobial Resistance. He holds a courtesy appointment as a Professor of Health Research Methods, Evidence & Impact (Part-Time) at McMaster University. He is an international lawyer licensed in both Ontario and New York who specializes in global health law, global governance and institutional design. His research leverages various methodological approaches to craft global strategies that better address transnational health threats and social inequalities. Past studies have focused on access to medicines, antimicrobial resistance, health misinformation, pandemics and tobacco control.

Margo Warren (Access to Medicine Foundation)

Margo Warren is the Government Engagement & Policy Manager within the Strategy Team at the Access to Medicine Foundation. In this role, she liaises with governments, private foundations and multilateral organisations that are actively working to improve global health and access to medicine in order to share the Foundation’s research findings and identify key opportunities for collaboration and change-making. She also manages the Foundation’s fundraising activities. Before taking on this role, she was a Researcher for the Access to Medicine Index, specialising in product deployment, including equitable pricing strategies, expedited registration techniques, and access oriented licensing.
Prior to joining the Foundation, Margo worked for the Ministry of Health and Long-Term Care in Ontario, Canada, in strategic health policy. In her position at the Ministry, Margo led the Priority Policy Team, working on the development of critical new initiatives aimed at improving access to medicine and strengthening health systems. 
Margo has held various health research and policy positions focused on partnerships for development, improving access to care, and addressing the social determinants of health. Margo holds both a bachelor’s degree and a master's degree in international development with a focus on health policy. Her research expertise is in exploring the complexities of producing affordable generic medications in low- and middle-income countries, including specifically analysing the domestic production of antiretrovirals as a viable option to help increase access to medicine.

Ghada Zoubiane (ICARS)

Dr Ghada Zoubiane is the Head of Partnership and Stakeholder Engagement at the International Centre for Antimicrobial Resistance Solutions (ICARS). In her role, she is shaping and delivering on ICARS’ efforts in antimicrobial resistance (AMR) intervention and implementation research, bridging the gap between evidence and practice and working in close partnership with low- and middle-income countries.
Ghada has over 20-year experience in both the public and private sector with the aim to advance health research. She was previously at the Wellcome Trust leading the science and innovation activities of their Drug-Resistant Infections priority programme. She spent over nine years at the UK Medical Research Council (MRC) developing and leading different areas of research including AMR, infectious diseases and public health. She established the UK cross-council initiative on AMR and the AMR Funders Forum in 2013 (comprising of more than 17 different funders) and represented the UK at the Management Board of the European Joint Programming Initiative for AMR.
Ghada has a strong appreciation of the science policy interface and the benefit of building strong partnerships across different stakeholders on a national and international level. Prior to the MRC, Ghada had experience in basic and translational research including early stage drug discovery and development within academia and the private sector.

Sabiha Essack (University of KwaZulu-Natal)

Professor Sabiha Essack (B. Pharm., M. Pharm., PhD) is the South African Research Chair (SARChI) in Antibiotic Resistance and One Health and Professor in Pharmaceutical Sciences at the University of KwaZulu-Natal (UKZN) in Durban, South Africa. She is Senior Implementation Research Advisor at the International Centre for Antimicrobial Resistance Solutions (ICARS) in Denmark and serves as expert consultant on antimicrobial resistance (AMR) and antimicrobial stewardship to the World Health Organization and its regional offices.  Professor Essack is chairperson of the Global Respiratory Infection Partnership (GRIP), serves on the Advisory Board of the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the Fleming Fund Expert Advisory Group, the Market Analysis Expert Advisory Group of the Global AMR Research and Development Hub convened by the German government and is a member of the Wellcome Trust Surveillance and Epidemiology of Drug Resistant Infections Consortium (SEDRIC).  She previously served on the South African Ministerial Advisory Committee on AMR, the International Pharmacy Federation Working Group on AMR, the South African Chapter of the Global Antibiotic Resistance Partnership (GARP) and the South African Antibiotic Stewardship Programme (SAASP).  Professor Essack was founder of the South African Chapter of the Alliance for the Prudent Use of Antibiotics (APUA).

Otto Cars (ReAct)

Otto Cars is senior professor of infectious diseases at Uppsala University, Sweden. He was one of the founders and the second president of the International Society of Anti-infective pharmacology (ISAP). In the mid -90´s he initiated the formation of a Swedish national multidisciplinary group for the rational use of antibiotics and containment of resistance, which was developed into the nation-wide network Strama (the Swedish strategic program against antibiotic resistance). Otto Cars was the chair of Strama from its inception in 1995 until 2011. He has been actively involved in numerous European and international initiatives in the area of antimicrobial resistance and has served as an expert to European Commission, the European Centre for Disease Prevention and Control and the European Medicines Agency. He has been member of the WHO Strategic and Technical Advisory Group (STAG) on antimicrobial resistance and the UN Interagency Coordination Group on Antimicrobial Resistance ( IACG)
Otto Cars´ engagement in the global consequences of antimicrobial resistance led in 2005 to the creation of the independent international network ReAct -Action on Antibiotic Resistance- which is funded primarily by the Swedish International development Cooperation Agency (Sida) and is working on all continents as a catalyst, advocating for and supporting multilevel engagement on antibiotic resistance.

Ramanan Laxminarayan (CDDEP & Princeton University)

Laxminarayan is founder and director of the Center for Disease Dynamics, Economics & Policy (CDDEP) in Washington, D.C. and New Delhi, and a senior research scholar at Princeton University. He is an affiliate professor at the University of Washington and a visiting professor at the University of Strathclyde in Scotland and at the University of Kwazulu Natal in South Africa. Laxminarayan chairs the board of GARDP, a global product development partnership created by the World Health Organization, that aims to develop and deliver new treatments for bacterial infections.  He is founder and board chair at HealthCubed, which works to improve access to healthcare and diagnostics worldwide.
Since 1995, Laxminarayan has worked to improve the understanding of antibiotic resistance as a problem of managing a shared global resource.  His work encompasses extensive peer-reviewed research, public outreach, and direct engagement across Asia and Africa through the Global Antibiotic Resistance Partnership. Through his prolific research, active public outreach (including a TED talk that has been viewed over a million times) and sustained policy engagement, he has played a central role in bringing the issue of drug resistance to the attention of leaders and policymakers worldwide and to the United Nations General Assembly in September 2016.
During the Obama Administration, Laxminarayan served on the U.S. President’s Council of Advisors on Science and Technology’s antimicrobial resistance working group and was appointed a voting member of the U.S. Presidential Advisory Council on Combating Antimicrobial Resistance.  He was recently appointed to a second term by the current administration. He is a series editor of the Disease Control Priorities for Developing Countries, 3rd edition.

Vetenskapsrådet is using Invajo´s event tool for managing this event and its attendees. Invajo have no responsibility for the execution of the event. Any questions regarding the event and its content will be answered by Vetenskapsrådet. For technical questions, please contact Invajo´s support. Your details are handled by Invajo, Vetenskapsrådet and different subcontractors that are required for the delivery of the products and functions provided by Invajo. By going through with a booking on this event, you also accept Invajos general conditions which are available on